MedTrace Logo

Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis

NCT07635043 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-06-09

No results posted yet for this study

Summary

To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad

Conditions

  • Psoriasis (PsO)

Interventions

DRUG

Betamethasone Dipropionate 0.05% Cream

Topical betamethasone dipropionate 0.05% cream once daily applied to affected plaque psoriasis lesions twice daily for up to 4 weeks

DRUG

Tapinarof Cream 1%

Topical tapinarof 1% cream applied once daily to affected skin areas for up to 12 weeks

Sponsors & Collaborators

  • Pakistan Institute of Medical Sciences

    lead OTHER_GOV

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2026-10-31
Completion
2026-11-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07635043 on ClinicalTrials.gov